KIN Insider Trading Activity and SEC Form 4 Filings
KIN insider trading summary
No open-market insider purchases or sales of Kindred Biosciences, Inc. (KIN) have been reported on SEC Form 4 in the past 12 months.
Latest KIN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 27, 2021 | Elanco Animal Health Inc | 10% Owner | Buy | $421.0M (45,508,938 @ $9.25) |
| Aug 2, 2021 | Richard Chin | Chief Executive Officer | Sell | $368K (40,000 @ $9.21) |
| Jul 2, 2021 | Richard Chin | Chief Executive Officer | Sell | $367K (40,000 @ $9.18) |
| Jun 16, 2021 | Richard Chin | Chief Executive Officer | Sell | $367K (40,000 @ $9.18) |
| Jun 4, 2021 | Park West Asset Management LLC | 10% Owner | Sell | $2.4M (345,383 @ $6.95) |
| Jun 3, 2021 | Park West Asset Management LLC | 10% Owner | Sell | $473K (69,600 @ $6.80) |
| Mar 17, 2021 | Denise Bevers | Director | Sell | $42K (8,396 @ $5.00) |
| Feb 22, 2021 | Denise Bevers | Director | Sell | $23K (4,622 @ $5.00) |
| Feb 19, 2021 | Denise Bevers | Director | Sell | $25 (5 @ $5.00) |
| Jan 29, 2021 | Park West Asset Management LLC | 10% Owner | Sell | $17K (3,300 @ $5.07) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.